13/10/2025 10:41
|
Medical, Health & Aged Care
* Results from the Phase 1b dose escalation of the TheraPb Phase 1/2 trial are the first clinical data for a Lead-212 (212Pb)-based-PSMA radioligand therapy
* The abstract presents a favorable..